^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Libtayo (cemiplimab-rwlc) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Non small cell lung cancer: Adenocarcinoma, Large Cell, NSCLC NOS...Preferred...Cemiplimab-rwlc + paclitaxel + (carboplatin or cisplatin)...
    Secondary therapy:
    carboplatin + paclitaxel; cisplatin + paclitaxel